Skip to main content
padlock icon - secure page this page is secure

Antidiabetic Medicinal Plants as a Source of Alpha Glucosidase Inhibitors

Buy Article:

$68.00 + tax (Refund Policy)

The aim of this study is to collate all available data on antidiabetic plants that inhibit alpha glucosidase, reported mainly by Medline (PubMed) these last years. In the present study, interest is focused on experimental researches conducted on hypoglycemic plants particularly those which show alpha glucosidase inhibitor activity alongside bioactive components.

This study describes 47 species that belong to 29 families. The plant families, which enclose the species, studied most as inhibitors of alphaglucosidase, are Fabaceae (6 species), Crassulaceae (3 species), Hippocrateacaea (3 species), Lamiaceae (3 sp.), and Myrtaceae (3 species), with most studied species being Salacia reticulata (Hippocrateaceae) and Morus alba (Moraceae).

The study also covers natural products (active natural components and crude extracts) isolated from the medicinal plants which inhibit alpha glucosidase as reported this last decade. Many kinds of these isolated natural products show strong activity such as, Alkaloids, stilbenoids (polyphenol), triterpene, acids (chlorogenic acid, betulinic acid, syringic acid, vanillic acid, bartogenic acid, oleanolic acid, dehydrotrametenolic acid, corosolic acid, ellagic acid, ursolic acid, gallic acid), phytosterol, myoinositol, flavonoids, Flavonolignans, anthraquinones, anthrones, and xanthones, Feruloylglucosides, flavanone glucosides, acetophenone glucosides, glucopyranoside derivatives, genine derivatives, flavonol, anthocyanin and others.

No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Antidiabetic; Glucosidase inhibitor; Glycaemic control; Intestine; Medicinal plants; α-Glucosidase

Document Type: Research Article

Publication date: July 1, 2010

More about this publication?
  • Current Diabetes Reviews publishes frontier reviews on all the latest advances on diabetes and its related areas e.g. pharmacology, pathogenesis, complications, epidemiology, clinical care, and therapy.

    The journal's aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians who are involved in the field of diabetes.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more